About
Andreas Loew is a Partner at Scion with more than 20 years in the pharmaceutical industry, specializing in protein engineering and structural biology. He founded and served as CSO of Marengo Therapeutics and previously led New Technologies for Biologics at Novartis, where he was principal inventor of core technologies behind the company's adoptive T-cell therapy portfolio and contributed to the FDA-approved CAR-T product Kymriah. He earned his PhD at the University of Bayreuth in Germany and completed postdoctoral training in biochemistry and structural biology at the University of Illinois, Birkbeck College London, and UT Southwestern Medical Center.
Contact· self-published, not guessed
Invests in
Biotech
Experience
- Scion Life SciencesPartnercurrent2022 — presentNew York
- BioCove LLCIndependent Consultant2021 — 2023Greater Boston
- Marengo TherapeuticsFounder, CSO2016 — 2020Cambridge
- Apple Tree PartnersEntrepreneur in Residence2015 — 2016Greater New York City Area
- Novartis Institutes for BioMedical ResearchExecutive Director, NIBR Biologics2015
- Novartis Institutes for BioMedical ResearchDirector, NIBR Biologics2011 — 2015
- Novartis Institutes for BioMedical ResearchSenior Research Investigator II, NIBR Biologics2009 — 2011
- Novartis Institutes for BioMedical ResearchSenior Research Investigator I, Center for Proteomic Research2006 — 2009
- Novartis Institutes for BioMedical ResearchResearch Investigator II, Discovery Technology2004 — 2006
- Novartis Institutes for BioMedical ResearchSenior Scientist III, Discovery Technology2003 — 2004
- Abbott Bioresearch CenterSenior Scientist I, X-ray Structural Biology2001 — 2003
- The University of Texas Southwestern Medical Center at DallasPost doc1999 — 2001Dallas/Fort Worth Area
- Birkbeck, University of LondonPost doc1996 — 1998
Skills & more
+11 more
BiotherapeuticsClinical DevelopmentClinical ResearchDrug DeliveryProtein EngineeringCancer ImmunotherapyOncologyProtein ChemistryPharmaceutical IndustryRNAtherapeutic mRNAFrom Andreas's professional profile.
Colleagues at Scion Life Sciences
Frequently asked questions
- Who is Andreas Loew?
- Andreas Loew is a Partner at Scion with more than 20 years in the pharmaceutical industry, specializing in protein engineering and structural biology. He founded and served as CSO of Marengo Therapeutics and previously led New Technologies for Biologics at Novartis, where he was principal inventor of core technologies behind the company's adoptive T-cell therapy portfolio and contributed to the FDA-approved CAR-T product Kymriah. He earned his PhD at the University of Bayreuth in Germany and completed postdoctoral training in biochemistry and structural biology at the University of Illinois, Birkbeck College London, and UT Southwestern Medical Center.
- Where does Andreas Loew work?
- Andreas Loew is Partner at Scion Life Sciences.
- What does Andreas Loew invest in?
- Andreas Loew invests in Biotech.
- Where did Andreas Loew go to school?
- Andreas Loew studied at University of Bayreuth (Doctor of Philosophy (Ph.D.), Biochemistry); RPTU Kaiserslautern-Landau (Master's degree, Chemistry); Birkbeck, University of London.
Founder mafias
Scion Life Sciences mafia6
Also came through, then founded or led a company.
Birkbeck, University of London mafia4
Also came through, then founded or led a company.
University of Bayreuth mafia3
Also came through, then founded or led a company.
RPTU Kaiserslautern-Landau mafia2
Also came through, then founded or led a company.
Same school
Also attended University of Bayreuth21
+ 15 more
Also attended RPTU Kaiserslautern-Landau8
+ 2 more
Also attended Birkbeck, University of London28
+ 22 more
Also attended The University of Texas Southwestern Medical School2
Shared employers
Also worked at Marengo Therapeutics1
Also worked at Apple Tree Partners8
+ 2 more
Also worked at Novartis Institutes for BioMedical Research130
+ 124 more
Also worked at Abbott Bioresearch Center41
+ 35 more


















:format(webp))






























